PARP1 and cancer: We propose that, once cancer cells spontaneously acquire cisplatin resistance, we can use a PARP inhibitor (instead of a still-controversial MYC inhibitor) to inhibit oncogenic MYC activity so that we can recover endogenous BIN1 expression and accompanying cisplatin sensitivity.